Literature DB >> 2386551

Effect of dipyridamole on transport and phosphorylation of thymidine and 3'-azido-3'-deoxythymidine in human monocyte/macrophages.

G V Betageri1, J Szebeni, K Hung, S S Patel, L M Wahl, M Corcoran, J N Weinstein.   

Abstract

Dipyridamole (DPM), a commonly used coronary vasodilator and antithrombotic drug, was shown recently to potentiate the antiviral effect of 3'-azido-3'-deoxythymidine (AZT) in HIV-1 infected human monocyte-derived macrophages (M/M) in vitro. We report in the present study that in uninfected M/M, DPM markedly inhibited cellular uptake of [3H]thymidine (dThd) and its incorporation into the nucleotide pools, particularly the dThd-triphosphate pool. In contrast, DPM did not affect cellular uptake and phosphorylation of [3H]AZT. Since dThd counteracts the phosphorylation and antiviral action of AZT, these findings support the hypothesis that the potentiation of the anti-HIV effect of AZT is due, at least in part, to differential inhibition of nucleoside salvage.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2386551     DOI: 10.1016/0006-2952(90)90328-i

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Effects of thymidine and uridine on the phosphorylation of 3'-azido-3'-deoxythymidine (zidovudine) in human mononuclear cells.

Authors:  J Szebeni; S S Patel; K Hung; L M Wahl; J N Weinstein
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

2.  Inhibition of herpes simplex virus reactivation by dipyridamole.

Authors:  R B Tenser; A Gaydos; K A Hay
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

3.  Differential inhibition of 2'-deoxycytidine salvage as a possible mechanism for potentiation of the anti-human immunodeficiency virus activity of 2',3'-dideoxycytidine by dipyridamole.

Authors:  S S Patel; J Szebeni; L M Wahl; J N Weinstein
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

4.  Effect of dipyridamole on zidovudine pharmacokinetics and short-term tolerance in asymptomatic human immunodeficiency virus-infected subjects.

Authors:  C W Hendrix; C Flexner; J Szebeni; S Kuwahara; S Pennypacker; J N Weinstein; P S Lietman
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

5.  Zidovudine azido-reductase in human liver microsomes: activation by ethacrynic acid, dipyridamole, and indomethacin and inhibition by human immunodeficiency virus protease inhibitors.

Authors:  S Fayz; T Inaba
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

Review 6.  Equilibrative Nucleoside Transporters 1 and 4: Which One Is a Better Target for Cardioprotection Against Ischemia-Reperfusion Injury?

Authors:  Cui Yang; George P H Leung
Journal:  J Cardiovasc Pharmacol       Date:  2015-06       Impact factor: 3.105

7.  Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients.

Authors:  Kholoud F Aliter; Rami A Al-Horani
Journal:  Curr Pharm Des       Date:  2021       Impact factor: 3.116

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.